Tag: antifungals industry trends

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Antifungals Market Growth Potential: How Will Market Size Shift Through 2030?

The antifungals market has experienced robust expansion in recent times. This market is projected to expand from $29.6 billion in 2025 to reach $31.98 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.1%. Historically, this expansion has been driven by factors such as a rise in hospital-acquired infections, the prevalent application of azoles, an increasing number of immunosuppressed individuals, well-established antifungal treatments, and the worldwide prevalence of mycoses.

The antifungals market is projected to experience robust expansion over the coming years. Its valuation is set to reach $44.96 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.9%. This anticipated growth during the forecast period is primarily driven by factors such as an increase in systemic fungal infections, rising concerns about antifungal resistance, a growing demand for safer therapeutic options, the expansion of hospital care services, and improved diagnosis rates. Key trends anticipated during this period encompass the increasing prevalence of fungal infections, an escalating need for broad-spectrum antifungal agents, the widening availability of topical antifungal treatments, enhanced application in patients with compromised immune systems, and the innovation of new classes of antifungal drugs.

Get A Free Sample Report With In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2442&type=smp&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Antifungals Market Growth Momentum: What Factors Are Shaping Demand?

The increasing prevalence of fungal infections is anticipated to propel the growth of the antifungals market moving forward. Fungal infections are conditions caused by fungi invading and growing within or on the body, affecting various parts such as the skin, nails, lungs, and mucous membranes. The rising incidence of these infections is attributed to climate change, which creates favorable environments for fungi to spread and adapt to higher temperatures, thereby increasing human exposure and infection risks. Antifungals play a crucial role in treating fungal diseases by inhibiting the growth and reproduction of fungi, either by disrupting their cell wall or membrane, blocking essential enzymatic processes, or interfering with their ability to synthesize vital components. This action reduces the fungal load, alleviates symptoms, and prevents the spread of infection within the body. For instance, in May 2025, according to the UK Health Security Agency, a UK-based government department, bloodstream infections caused by yeast increased by 4% in 2024 compared with 2023, rising from 2,170 reported cases to 2,247. Consequently, the increasing incidence of fungal infections is a key factor driving the expansion of the antifungals market. The expansion of healthcare infrastructure is projected to fuel the growth of the antifungals market in the future. Healthcare infrastructure refers to the foundational physical and organizational frameworks, facilities, and systems that facilitate the provision of healthcare services. The primary driver behind the rise in healthcare infrastructure is increased government backing and financial commitments, channeled through various policies and incentives aimed at advancing healthcare facility development. This infrastructure provides the essential facilities, systems, and resources required for effective management of fungal infections. For illustration, in May 2024, according to Baker McKenzie, an Australia based law firm, the Australian government allocated $1.82 billion (AUD 2.8 billion) to strengthen Medicare, building on the $3.95 billion (AUD 6.1 billion) Medicare investment in the 2023-24 Federal Budget, along with USD 91.48million (AUD 141.1 million) designated for medical research and services for individuals with chronic conditions such as bowel and skin cancer, diabetes, and dementia. Therefore, the expanding healthcare infrastructure is a significant factor propelling the antifungals market forward.

Antifungals Market Segments: Where Is Growth Concentrated?

The antifungals market covered in this report is segmented –

1) By Drug Type: Echinocandins, Azoles, Polyenes, Allylamines

2) By Route of Administration: Oral, Parenteral, Topical

3) By End users: Hospitals & Clinics, Dermatology clinics, Other Users

Subsegments:

1) By Echinocandins: Caspofungin, Micafungin, Anidulafungin

2) By Azoles: Fluconazole, Itraconazole, Voriconazole, Posaconazole, Ketoconazole

3) By Polyenes: Amphotericin B, Nystatin

4) By Allylamines: Terbinafine, Naftifine

Antifungals Market Trends Redefining Industry Growth

Major corporations operating in the antifungals market are concentrating on developing innovative products and formulations, including long-acting echinocandin therapies. This initiative aims to bolster patient compliance, diminish the need for frequent dosing, and fulfill unmet clinical requirements concerning invasive fungal infections. Through extending their half-life and modifying their pharmacokinetics, these advanced antifungals provide effective fungal suppression with more convenient administration regimens. For example, in March 2023, Cidara Therapeutics, a US-based biotechnology company, alongside Melinta Therapeutics (U.S.), publicized the FDA’s clearance for REZZAYO (rezafungin for injection) for managing candidemia and invasive candidiasis. Rezafungin is an echinocandin administered once-weekly, exhibiting non-inferior effectiveness compared to daily caspofungin in clinical trials (ReSTORE Phase 3), while possessing a comparable safety record. The prolonged dosing potential of REZZAYO addresses a significant deficiency in antifungal treatment, thereby enhancing treatment consistency and easing the load on hospitals in acute-care settings.

Antifungals Market Key Participants And Competitive Landscape

Major companies operating in the antifungals market are Pfizer Inc., Novartis International AG, Merck & Co. Inc., Bayer AG, Abbott Laboratories, Sanofi S.A., Kramer Laboratories Inc., GlaxoSmithKline plc, Gilead Sciences Inc., Basilea Pharmaceutica AG, Sigma-Aldrich, Astellas Pharma Inc., Janssen Pharmaceutica NV, Zydus Cadila Healthcare Ltd., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma Co. Ltd., Scynexis Inc., Mayne Pharma Inc., Cosmo Pharmaceuticals NV, Leadiant Biosciences Inc, Glenmark Pharmaceuticals Limited, Cidara Therapeutics, MATINAS BIOPHARMA, Mylan N.V., Perrigo Company plc, Wockhardt Ltd., Lupin Limited, Dr. Reddy’s Laboratories Ltd, Torrent Pharmaceuticals Ltd., Hikma Pharmaceuticals PLC, Mayne Pharma Group Limited, Fresenius Kabi AG, Baxter International Inc., Akorn Operating Company LLC, Amphastar Pharmaceuticals Inc., Mylan Institutional LLC, West-Ward Pharmaceuticals Corp., Gland Pharma Limited, Aurobindo Pharma Limited

View The Full Antifungals Market Report:

https://www.thebusinessresearchcompany.com/report/antifungals-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Antifungals Market Regional Analysis And Leading Geography

North America was the largest region in the drugs for antifungals market in 2025. The Middle East is expected to be the fastest-growing region in the antifungals market. The regions covered in the antifungals market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Antifungals Market Expansion From $31.97 Billion In 2026 To $44.96 Billion In 2030

The market for antifungal medications has seen significant expansion over the past few years. Projections indicate that it will climb from $29.6 billion in 2025 to $31.98 billion in 2026, reflecting a compound annual growth rate (CAGR) of 8.1%. This historic growth was primarily driven by a rise in hospital-acquired infections, extensive utilization of azoles, a growing population with compromised immune systems, the availability of established antifungal treatments, and the ongoing global impact of mycoses.

The market for antifungal drugs is anticipated to experience significant expansion over the coming years, with projections indicating it could reach $44.96 billion by 2030, driven by a compound annual growth rate (CAGR) of 8.9%. This upward trajectory during the forecast period is fueled by several factors, including the rising incidence of systemic fungal infections, growing concerns over antifungal resistance, an increasing need for safer therapeutic options, the broadening scope of hospital-based care, and higher rates of disease diagnosis. Key developments shaping this period encompass a higher prevalence of fungal diseases, a surge in the demand for broad-spectrum agents, the widespread adoption of topical treatments, more frequent application in patients with compromised immune systems, and the advent of innovative classes of antifungal drugs.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2442&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Antifungals Market Demand Drivers Creating New Revenue Opportunities

The anticipated expansion of the antifungals market is being driven forward by a growing incidence of fungal infections. These infections arise when fungi invade and proliferate within or on the body, impacting areas like the skin, nails, lungs, and mucous membranes. Their increasing frequency is largely attributed to climate change, which fosters conditions that allow fungi to spread and adapt to warmer temperatures, thereby heightening human exposure and infection risks. Antifungals are essential in managing these diseases by curbing fungal growth and reproduction through mechanisms such as disrupting cell walls or membranes, impeding crucial enzymatic functions, or obstructing the synthesis of vital components. This reduces the fungal burden, eases symptoms, and curbs the infection’s spread within the body. For example, in May 2025, the UK Health Security Agency reported that yeast-induced bloodstream infections rose by 4% in 2024 compared to 2023, climbing from 2,170 to 2,247 cases. Consequently, the rising rate of fungal infections is fueling the antifungals market’s growth.

The antifungals market is expected to benefit from an expanding healthcare infrastructure, which is set to drive its growth in the coming years. This infrastructure encompasses the physical and organizational frameworks, facilities, and systems that enable healthcare delivery, with its growth largely fueled by heightened government backing and investments through policies and incentives that encourage the development of medical facilities. Such infrastructure provides the essential facilities, systems, and resources needed for effective management of fungal infections. A case in point is May 2024, when Baker McKenzie noted that the Australian government allocated $1.82 billion (AUD 2.8 billion) to bolster Medicare, supplementing the $3.95 billion (AUD 6.1 billion) Medicare investment from the 2023-24 Federal Budget, along with $91.48 million (AUD 141.1 million) for medical research and care for individuals with chronic conditions like bowel and skin cancer, diabetes, and dementia. Thus, the ongoing enhancement of healthcare infrastructure is accelerating the antifungals market’s growth.

Antifungals Market Segment Landscape: Which Areas Lead Market Development?

The antifungals market covered in this report is segmented –

1) By Drug Type: Echinocandins, Azoles, Polyenes, Allylamines

2) By Route of Administration: Oral, Parenteral, Topical

3) By End users: Hospitals & Clinics, Dermatology clinics, Other Users

Subsegments:

1) By Echinocandins: Caspofungin, Micafungin, Anidulafungin

2) By Azoles: Fluconazole, Itraconazole, Voriconazole, Posaconazole, Ketoconazole

3) By Polyenes: Amphotericin B, Nystatin

4) By Allylamines: Terbinafine, Naftifine

Antifungals Market Trends Driving Strategic Industry Expansion

Leading players in the antifungals market are prioritizing innovations such as long-acting echinocandin formulations aimed at enhancing patient compliance, minimizing dosing frequency, and tackling unmet needs in severe fungal infections. These advanced antifungal agents achieve prolonged fungal suppression through extended half-lives and optimized pharmacokinetics, allowing for more practical administration schedules. A notable example is the March 2023 FDA approval of REZZAYO (rezafungin for injection) for candidemia and invasive candidiasis, developed by Cidara Therapeutics and Melinta Therapeutics, both U.S.-based companies. As a once-weekly echinocandin, rezafungin demonstrated non-inferior efficacy relative to daily caspofungin in the ReSTORE Phase 3 trials, along with a comparable safety profile. By enabling less frequent dosing, REZZAYO fills an important void in antifungal care, boosting treatment continuity and easing the strain on hospital resources in acute environments.

Antifungals Market Industry Leaders And Market Competition

Major companies operating in the antifungals market are Pfizer Inc., Novartis International AG, Merck & Co. Inc., Bayer AG, Abbott Laboratories, Sanofi S.A., Kramer Laboratories Inc., GlaxoSmithKline plc, Gilead Sciences Inc., Basilea Pharmaceutica AG, Sigma-Aldrich, Astellas Pharma Inc., Janssen Pharmaceutica NV, Zydus Cadila Healthcare Ltd., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma Co. Ltd., Scynexis Inc., Mayne Pharma Inc., Cosmo Pharmaceuticals NV, Leadiant Biosciences Inc, Glenmark Pharmaceuticals Limited, Cidara Therapeutics, MATINAS BIOPHARMA, Mylan N.V., Perrigo Company plc, Wockhardt Ltd., Lupin Limited, Dr. Reddy’s Laboratories Ltd, Torrent Pharmaceuticals Ltd., Hikma Pharmaceuticals PLC, Mayne Pharma Group Limited, Fresenius Kabi AG, Baxter International Inc., Akorn Operating Company LLC, Amphastar Pharmaceuticals Inc., Mylan Institutional LLC, West-Ward Pharmaceuticals Corp., Gland Pharma Limited, Aurobindo Pharma Limited

Access The Complete Antifungals Market Report:

https://www.thebusinessresearchcompany.com/report/antifungals-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Antifungals Market Regional Distribution: Which Areas Drive Market Expansion?

North America was the largest region in the drugs for antifungals market in 2025. The Middle East is expected to be the fastest-growing region in the antifungals market. The regions covered in the antifungals market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Will The Market Value Of The Antifungals Market Grow Between 2026 And 2030?

The antifungals market size has experienced significant growth in recent years. It is projected to expand from $29.6 billion in 2025 to $31.98 billion in 2026, registering a compound annual growth rate (CAGR) of 8.1%. The expansion observed in the historic period stems from factors such as an increase in hospital-acquired infections, the widespread use of azoles, a rising immunosuppressed population, established antifungal therapies, and the global burden of mycoses.

The antifungals market is projected to experience substantial expansion over the upcoming years. By 2030, this market is anticipated to reach $44.96 billion, demonstrating a compound annual growth rate (CAGR) of 8.9%. This projected growth is driven by several factors, including an increase in systemic fungal infections, worries about antifungal resistance, a need for safer treatment options, the expansion of hospital services, and improved diagnosis rates. Key trends expected during this period involve a rising occurrence of fungal infections, an increasing call for broad-spectrum antifungal agents, the proliferation of topical antifungal remedies, their greater application in immunocompromised individuals, and the creation of new classes of antifungal drugs.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2442&type=smp

What Primary Drivers Are Shaping The Antifungals Market?

The escalating occurrence of fungal infections is anticipated to stimulate the expansion of the antifungals market in the future. Fungal infections are illnesses resulting from fungi invading and growing within or on the body, impacting various areas such as the skin, nails, lungs, and mucous membranes. The increasing frequency of fungal infections can be attributed to climate change, which fosters conditions suitable for fungi to spread and adapt to elevated temperatures, thereby heightening human exposure and infection risks. Antifungals are vital in treating fungal diseases by hindering fungal growth and reproduction, either by damaging their cell wall or membrane, obstructing critical enzymatic processes, or impeding their ability to synthesize essential components, consequently diminishing fungal load, alleviating symptoms, and preventing the spread of infection within the body. For example, in May 2025, according to the UK Health Security Agency, a UK-based government department, bloodstream infections caused by yeast saw a 4% increase in 2024 compared with 2023, rising from 2,170 reported cases to 2,247. Hence, the growing incidence of fungal infections is a key factor propelling the antifungals market. The expansion of healthcare infrastructure is expected to propel the antifungals market forward. Healthcare infrastructure encompasses the physical and organizational structures, facilities, and systems that facilitate the provision of healthcare services. This rise in healthcare infrastructure is primarily driven by increased government support and investments, delivered through various policies and incentives that encourage the development of healthcare facilities. This infrastructure comprises the necessary facilities, systems, and resources required for delivering effective healthcare services for the management of fungal infections. For instance, in May 2024, Baker McKenzie, an Australia based law firm, reported that the Australian government allocated $1.82 billion (AUD 2.8 billion) to strengthen Medicare, building upon the $3.95 billion (AUD 6.1 billion) Medicare investment from the 2023-24 Federal Budget, and an additional USD 91.48million (AUD 141.1 million) for medical research and services for individuals living with chronic conditions such as bowel and skin cancer, diabetes, and dementia. Therefore, the expanding healthcare infrastructure is a significant driver for the growth of the antifungals market.

Which Segment Categories Are Included In The Antifungals Market Segment Analysis?

The antifungals market covered in this report is segmented –

1) By Drug Type: Echinocandins, Azoles, Polyenes, Allylamines

2) By Route of Administration: Oral, Parenteral, Topical

3) By End users: Hospitals & Clinics, Dermatology clinics, Other Users

Subsegments:

1) By Echinocandins: Caspofungin, Micafungin, Anidulafungin

2) By Azoles: Fluconazole, Itraconazole, Voriconazole, Posaconazole, Ketoconazole

3) By Polyenes: Amphotericin B, Nystatin

4) By Allylamines: Terbinafine, Naftifine

What Trends Are Affecting The Direction Of The Antifungals Market?

Major companies in the antifungals market are concentrating on product innovation and new formulations, such as long-acting echinocandin therapies, to boost patient adherence, decrease dosing frequency, and address outstanding clinical requirements for invasive fungal infections. By increasing their half-life and modifying pharmacokinetics, these next-generation antifungals ensure effective fungal suppression with more convenient administration schedules. For instance, in March 2023, Cidara Therapeutics, a US-based biotechnology company, alongside Melinta Therapeutics (U.S.), announced FDA approval for REZZAYO (rezafungin for injection) for managing candidemia and invasive candidiasis. Rezafungin functions as a once-weekly echinocandin, proving non-inferior efficacy compared to daily caspofungin in clinical trials (ReSTORE Phase 3), while maintaining a comparable safety profile. The extended dosing capability of REZZAYO bridges a significant gap in antifungal therapy, improving treatment continuity and lessening the hospital burden in acute-care settings.

Who Are The Active Companies Shaping The Antifungals Market?

Major companies operating in the antifungals market are Pfizer Inc., Novartis International AG, Merck & Co. Inc., Bayer AG, Abbott Laboratories, Sanofi S.A., Kramer Laboratories Inc., GlaxoSmithKline plc, Gilead Sciences Inc., Basilea Pharmaceutica AG, Sigma-Aldrich, Astellas Pharma Inc., Janssen Pharmaceutica NV, Zydus Cadila Healthcare Ltd., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma Co. Ltd., Scynexis Inc., Mayne Pharma Inc., Cosmo Pharmaceuticals NV, Leadiant Biosciences Inc, Glenmark Pharmaceuticals Limited, Cidara Therapeutics, MATINAS BIOPHARMA, Mylan N.V., Perrigo Company plc, Wockhardt Ltd., Lupin Limited, Dr. Reddy’s Laboratories Ltd, Torrent Pharmaceuticals Ltd., Hikma Pharmaceuticals PLC, Mayne Pharma Group Limited, Fresenius Kabi AG, Baxter International Inc., Akorn Operating Company LLC, Amphastar Pharmaceuticals Inc., Mylan Institutional LLC, West-Ward Pharmaceuticals Corp., Gland Pharma Limited, Aurobindo Pharma Limited

Get The Full Antifungals Market Report:

https://www.thebusinessresearchcompany.com/report/antifungals-global-market-report

Which Region Holds The Highest Market Share In The Antifungals Market?

North America was the largest region in the drugs for antifungals market in 2025. The Middle East is expected to be the fastest-growing region in the antifungals market. The regions covered in the antifungals market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Antifungals Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/antifungals-global-market-report

Browse Through More Reports Similar to the Global Antifungals Market 2026, By The Business Research Company

Antifungals Market Report 2026

https://www.thebusinessresearchcompany.com/report/antifungals-global-market-report

Fungicides Market Report 2026

https://www.thebusinessresearchcompany.com/report/fungicides-global-market-report

Candidiasis Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/candidiasis-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Estimated Market Size Of The Antifungals Market During 2026–2030?

The antifungals market size has seen robust growth in recent years. This market is projected to expand from $29.6 billion in 2025 to $31.98 billion in 2026, driven by a compound annual growth rate (CAGR) of 8.1%. Several factors contributed to its historical growth, including an increase in hospital-acquired infections, the widespread adoption of azoles, a growing immunosuppressed population, the availability of established antifungal therapies, and the global prevalence of mycoses.

The antifungals market is projected to experience substantial expansion over the upcoming years. This market is forecast to reach $44.96 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.9%. The anticipated growth during this period stems from factors such as an increase in systemic fungal infections, worries about antifungal resistance, a need for safer treatments, the expansion of hospital services, and improved diagnosis rates. Key trends foreseen for the same period encompass a higher incidence of fungal infections, an escalating need for broad-spectrum antifungal agents, the proliferation of topical antifungal remedies, greater application in individuals with compromised immune systems, and the emergence of new classes of antifungal drugs.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2442&type=smp

What Drivers Are Expected To Influence The Antifungals Market During The Forecast Period?

The expanding prevalence of fungal infections is anticipated to boost the antifungals market going forward. Fungal infections are illnesses resulting from fungi invading and multiplying within or on the body, affecting various regions such as the skin, nails, lungs, and mucous membranes. The rising incidence of these infections is attributed to climate change creating conditions that encourage fungi to spread and adapt to elevated temperatures, thereby increasing human exposure and infection risks. Antifungals are essential for treating fungal diseases by inhibiting the growth and reproduction of fungi, either by disrupting their cell wall or membrane, blocking vital enzymatic processes, or interfering with their ability to synthesize crucial components, which in turn reduces the fungal load, alleviates symptoms, and prevents the infection from spreading throughout the body. For instance, in May 2025, according to the UK Health Security Agency, a UK-based government department, bloodstream infections caused by yeast increased by 4% in 2024 compared with 2023, rising from 2,170 reported cases to 2,247. Thus, the growing occurrence of fungal infections is propelling the growth of the antifungals market.

How Are The Various Segments Of The Antifungals Market Categorized?

The antifungals market covered in this report is segmented –

1) By Drug Type: Echinocandins, Azoles, Polyenes, Allylamines

2) By Route of Administration: Oral, Parenteral, Topical

3) By End users: Hospitals & Clinics, Dermatology clinics, Other Users

Subsegments:

1) By Echinocandins: Caspofungin, Micafungin, Anidulafungin

2) By Azoles: Fluconazole, Itraconazole, Voriconazole, Posaconazole, Ketoconazole

3) By Polyenes: Amphotericin B, Nystatin

4) By Allylamines: Terbinafine, Naftifine

What Trends Are Affecting The Expansion Of The Antifungals Market?

Leading companies within the antifungals market are prioritizing advancements in product design and formulation, including the development of long-acting echinocandin therapies. This focus aims to enhance patient compliance, decrease the frequency of drug administration, and satisfy pressing clinical requirements for invasive fungal infections. Through the extension of drug half-life and alterations to pharmacokinetics, these contemporary antifungals provide efficient fungal control alongside more user-friendly dosing regimens. A notable example occurred in March 2023 when Cidara Therapeutics, a US-based biotechnology firm, in collaboration with Melinta Therapeutics (U.S.), declared that REZZAYO (rezafungin for injection) had received FDA approval for managing candidemia and invasive candidiasis. Rezafungin, a once-weekly echinocandin, demonstrated non-inferior efficacy when contrasted with daily caspofungin in the ReSTORE Phase 3 clinical trials, all while exhibiting a similar safety profile. The potential for extended dosing offered by REZZAYO addresses a significant deficiency in current antifungal treatments, thereby fostering improved continuity of care and alleviating the burden on hospitals in acute-care environments.

Which Major Firms Influence Developments In The Antifungals Market?

Major companies operating in the antifungals market are Pfizer Inc., Novartis International AG, Merck & Co. Inc., Bayer AG, Abbott Laboratories, Sanofi S.A., Kramer Laboratories Inc., GlaxoSmithKline plc, Gilead Sciences Inc., Basilea Pharmaceutica AG, Sigma-Aldrich, Astellas Pharma Inc., Janssen Pharmaceutica NV, Zydus Cadila Healthcare Ltd., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma Co. Ltd., Scynexis Inc., Mayne Pharma Inc., Cosmo Pharmaceuticals NV, Leadiant Biosciences Inc, Glenmark Pharmaceuticals Limited, Cidara Therapeutics, MATINAS BIOPHARMA, Mylan N.V., Perrigo Company plc, Wockhardt Ltd., Lupin Limited, Dr. Reddy’s Laboratories Ltd, Torrent Pharmaceuticals Ltd., Hikma Pharmaceuticals PLC, Mayne Pharma Group Limited, Fresenius Kabi AG, Baxter International Inc., Akorn Operating Company LLC, Amphastar Pharmaceuticals Inc., Mylan Institutional LLC, West-Ward Pharmaceuticals Corp., Gland Pharma Limited, Aurobindo Pharma Limited

Read the full antifungals market report here:

https://www.thebusinessresearchcompany.com/report/antifungals-global-market-report

Which Region Is Forecast To Lead The Antifungals Market In Terms Of Market Size?

North America was the largest region in the drugs for antifungals market in 2025. The Middle East is expected to be the fastest-growing region in the antifungals market. The regions covered in the antifungals market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Antifungals Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=2442&type=smp

Browse Through More Reports Similar to the Global Antifungals Market 2026, By The Business Research Company

Antifungals Market Report 2026

https://www.thebusinessresearchcompany.com/report/antifungals-global-market-report

Fungicides Market Report 2026

https://www.thebusinessresearchcompany.com/report/fungicides-global-market-report

Candidiasis Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/candidiasis-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the antifungals market from 2026–2035 with trusted insights from The Business Research Company

What level of CAGR-driven expansion is anticipated in the Antifungals Market between 2026 and 2030?

The antifungals market size has demonstrated strong expansion in recent years. It is projected to increase from $29.6 billion in 2025 to $31.98 billion in 2026, registering a compound annual growth rate (CAGR) of 8.1%. The growth observed in the past can be attributed to several factors including an increase in hospital-acquired infections, the widespread adoption of azoles, a growing immunosuppressed population, established antifungal therapies, and the global burden of mycoses.

The antifungals market is anticipated to witness robust expansion in the forthcoming years. It is projected to reach $44.96 billion by 2030, progressing at a compound annual growth rate (CAGR) of 8.9%. This forecasted growth can be ascribed to an increase in systemic fungal infections, growing concerns regarding antifungal resistance, the demand for more secure therapies, the expansion of hospital care facilities, and enhanced diagnosis rates. Significant trends during this period involve the rising occurrence of fungal infections, an escalating need for broad-spectrum antifungals, the proliferation of topical antifungal treatments, augmented application in immunocompromised individuals, and the creation of innovative antifungal drug classes.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2442&type=smp

What Drivers Are Affecting Demand-Supply Dynamics In The Antifungals Market?

The growth of the antifungals market is anticipated to be driven by the rising occurrence of fungal infections. These infections, which involve fungi growing in or on the body, can impact areas like the skin, nails, lungs, and mucous membranes. The increased prevalence is linked to climate change, which fosters environments where fungi can proliferate and adapt to higher temperatures, thus escalating human exposure and infection risks. Antifungals are vital for treating these conditions by hindering fungal growth and reproduction, achieved through mechanisms such as disrupting their cell walls or membranes, impeding essential enzymatic processes, or interfering with vital component synthesis. This action reduces fungal load, alleviates symptoms, and prevents infection dissemination within the body. As an illustration, the UK Health Security Agency reported in May 2025 that bloodstream infections from yeast rose by 4% in 2024 compared to 2023, with cases increasing from 2,170 to 2,247. Consequently, the growing incidence of fungal infections is a key factor propelling the expansion of the antifungals market.

What Segments Are Included Within The Antifungals Market?

The antifungals market covered in this report is segmented –

1) By Drug Type: Echinocandins, Azoles, Polyenes, Allylamines

2) By Route of Administration: Oral, Parenteral, Topical

3) By End users: Hospitals & Clinics, Dermatology clinics, Other Users

Subsegments:

1) By Echinocandins: Caspofungin, Micafungin, Anidulafungin

2) By Azoles: Fluconazole, Itraconazole, Voriconazole, Posaconazole, Ketoconazole

3) By Polyenes: Amphotericin B, Nystatin

4) By Allylamines: Terbinafine, Naftifine

Which Trends Are Guiding The Evolution Of The Antifungals Market?

Major companies in the antifungals market are focusing on product innovation and new formulations, including long-acting echinocandin therapies, to improve patient adherence, reduce how often doses are needed, and meet unaddressed clinical needs in invasive fungal infections. These newer antifungals provide effective fungal suppression through more convenient administration schedules by extending their half-life and altering their pharmacokinetics. As an example, in March 2023, Cidara Therapeutics, a US-based biotechnology company, alongside Melinta Therapeutics (U.S.), announced that the FDA had approved REZZAYO (rezafungin for injection) for treating candidemia and invasive candidiasis. Rezafungin is a once-weekly echinocandin that showed non-inferior efficacy compared to daily caspofungin in clinical trials (ReSTORE Phase 3), while also having a comparable safety profile. The extended dosing capability of REZZAYO addresses a vital gap in antifungal therapy, enhancing treatment continuity and easing the burden on hospitals in acute-care settings.

Who Are The Prominent Global Companies Shaping The Antifungals Market Landscape?

Major companies operating in the antifungals market are Pfizer Inc., Novartis International AG, Merck & Co. Inc., Bayer AG, Abbott Laboratories, Sanofi S.A., Kramer Laboratories Inc., GlaxoSmithKline plc, Gilead Sciences Inc., Basilea Pharmaceutica AG, Sigma-Aldrich, Astellas Pharma Inc., Janssen Pharmaceutica NV, Zydus Cadila Healthcare Ltd., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma Co. Ltd., Scynexis Inc., Mayne Pharma Inc., Cosmo Pharmaceuticals NV, Leadiant Biosciences Inc, Glenmark Pharmaceuticals Limited, Cidara Therapeutics, MATINAS BIOPHARMA, Mylan N.V., Perrigo Company plc, Wockhardt Ltd., Lupin Limited, Dr. Reddy’s Laboratories Ltd, Torrent Pharmaceuticals Ltd., Hikma Pharmaceuticals PLC, Mayne Pharma Group Limited, Fresenius Kabi AG, Baxter International Inc., Akorn Operating Company LLC, Amphastar Pharmaceuticals Inc., Mylan Institutional LLC, West-Ward Pharmaceuticals Corp., Gland Pharma Limited, Aurobindo Pharma Limited

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/antifungals-global-market-report

Which Geographic Areas Are Emerging As Strong Markets For The Antifungals Market?

North America was the largest region in the drugs for antifungals market in 2025. The Middle East is expected to be the fastest-growing region in the antifungals market. The regions covered in the antifungals market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Antifungals Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=2442&type=smp

Browse Through More Reports Similar to the Global Antifungals Market 2026, By The Business Research Company

Antifungals Market Report 2026

https://www.thebusinessresearchcompany.com/report/antifungals-global-market-report

Fungicides Market Report 2026

https://www.thebusinessresearchcompany.com/report/fungicides-global-market-report

Candidiasis Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/candidiasis-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the photodynamic therapy market from 2025–2034 with trusted insights from The Business Research Company

How Will The Photodynamic Therapy Market Size Evolve Between Now And 2029?

The antifungals market has shown significant growth in recent years. This market is projected to expand from $27.16 billion in 2024 to $29.6 billion in 2025, achieving a compound annual growth rate (CAGR) of 9.0%. Historically, this expansion has been driven by factors such as the prevalence of fungal diseases, an aging global population, developments in healthcare infrastructure, and increased awareness and education.

The antifungals market is anticipated to show significant expansion over the next few years. It is forecast to expand to “$41.2 billion by 2029, achieving a compound annual growth rate (CAGR) of 8.6%. The expansion during the projected period stems from factors such as evolving fungal strains, governmental regulatory approvals, widespread global health issues, increased spending on healthcare, and enhanced patient education and awareness. Prominent developments expected in this forecast period involve dedicated research and development, the rise of telemedicine and e-health services, continuous advancements in antifungal drug creation, and various collaborations and partnerships.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2442&type=smp

Which Key Drivers Are Powering Growth In The Photodynamic Therapy Market?

The rising occurrence of fungal infections is anticipated to boost the expansion of the antifungals market in the future. These are illnesses resulting from fungi invading and growing within or on the body, capable of impacting diverse areas such as the skin, nails, lungs, and mucous membranes. This rise in prevalence stems from several contributing factors, including an increase in immunocompromised individuals, climate change fostering conditions conducive to fungal growth, the greater use of broad-spectrum antibiotics disrupting natural microbiomes, inadequate hygiene, urbanization, and the expanding incidence of chronic diseases like diabetes which heighten susceptibility to these infections. Antifungal agents are vital in managing fungal diseases. They work by hindering the growth and replication of fungi, either through disturbing their cell walls or membranes, obstructing key enzymatic processes, or impeding their synthesis of crucial components. This action ultimately decreases the fungal burden, eases symptoms, and halts the infection’s spread throughout the body. For example, data from September 2024, provided by the International Society For Infectious Diseases, a US-based non-profit organization, indicated an annual occurrence of 6.5 million invasive fungal infections. These were linked to approximately 3.8 million mortalities, with 2.5 million (68%; range 35-90%) of these deaths directly caused by such infections. Consequently, the escalating incidence of fungal infections is projected to propel the antifungals market.

How Is The Global Photodynamic Therapy Market Structured By Key Segments?

The antifungals market covered in this report is segmented –

1) By Drug Type: Echinocandins, Azoles, Polyenes, Allylamines

2) By Route of Administration: Oral, Parenteral, Topical

3) By End users: Hospitals & Clinics, Dermatology clinics, Other Users

Subsegments:

1) By Echinocandins: Caspofungin, Micafungin, Anidulafungin

2) By Azoles: Fluconazole, Itraconazole, Voriconazole, Posaconazole, Ketoconazole

3) By Polyenes: Amphotericin B, Nystatin

4) By Allylamines: Terbinafine, Naftifine

What Future-Focused Trends Are Anticipated In The Photodynamic Therapy Market?

Pharmaceutical developers and manufacturers are enhancing their various departments, including research and development, marketing, and manufacturing, by forming collaborations and strategic partnerships with other organizations and research institutions, with the goal of expanding their product portfolios. Consequently, businesses within the anti-infective drugs market should evaluate strategic collaborations to broaden their operational scope and product offerings, which will help them increase revenue and remain competitive in the market.

Which Companies Hold A Competitive Edge In The Photodynamic Therapy Market?

Major companies operating in the antifungals market include Pfizer Inc., Novartis International AG, Merck & Co. Inc., Bayer AG, Abbott Laboratories, Sanofi S.A., Kramer Laboratories Inc., GlaxoSmithKline plc, Gilead Sciences Inc., Basilea Pharmaceutica AG, Sigma-Aldrich, Astellas Pharma Inc., Janssen Pharmaceutica NV, Zydus Cadila Healthcare Ltd., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma Co. Ltd., Scynexis Inc., Mayne Pharma Inc., Cosmo Pharmaceuticals NV, Leadiant Biosciences Inc, Glenmark Pharmaceuticals Limited, Cidara Therapeutics, MATINAS BIOPHARMA, Mylan N.V., Perrigo Company plc, Wockhardt Ltd., Lupin Limited, Dr. Reddy’s Laboratories Ltd, Torrent Pharmaceuticals Ltd., Hikma Pharmaceuticals PLC, Mayne Pharma Group Limited, Fresenius Kabi AG, Baxter International Inc., Akorn Operating Company LLC, Amphastar Pharmaceuticals Inc., Mylan Institutional LLC, West-Ward Pharmaceuticals Corp., Gland Pharma Limited, Aurobindo Pharma Limited

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/antifungals-global-market-report

Which Region Is Expected To Lead The Photodynamic Therapy Market In The Next Few Years?

North America was the largest region in the drugs for antifungals market in 2024. The Middle East is expected to be the fastest-growing region in the antifungals market. The regions covered in the antifungals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=2442&type=smp

Browse Through More Reports Similar to the Global Photodynamic Therapy Market 2025, By The Business Research Company

Gastrointestinal Drug Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastrointestinal-drug-global-market-report

Smart Pills Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/smart-pills-global-market-report

Organ On Chip Market 2025

https://www.thebusinessresearchcompany.com/report/organ-on-chip-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Expected Total Market Size Of The Antifungals Industry By The Forecast Year 2029?

The antifungals market has shown significant expansion in recent years. Its valuation is projected to rise from $27.16 billion in 2024 to reach $29.6 billion in 2025, progressing at a compound annual growth rate (CAGR) of 9.0%. The expansion observed historically can be attributed to factors like the prevalence of fungal diseases, an aging global population, developments in healthcare infrastructure, and increased awareness and education.

The antifungals market is projected to undergo significant expansion in the foreseeable future. It is set to expand to $41.2 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 8.6%. This anticipated growth throughout the forecast period stems from factors such as the rise of new fungal strains, the approval of new regulations, escalating global health concerns, increased investment in healthcare, and enhanced patient education and awareness initiatives. Prominent trends expected in this period include intensified research and development, the growth of telemedicine and e-health, progress in developing antifungal medications, and strategic collaborations and partnerships.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2442&type=smp

Which Drivers Are Supporting Growth Of The Antifungals Market?

The expanding occurrence of fungal infections is anticipated to boost the development of the antifungals market in the future. Fungal infections are conditions resulting from fungi entering and multiplying within or on the body. Fungi have the potential to impact diverse areas of the body, such as the skin, nails, lungs, and mucous membranes. The rising incidence of these infections can be attributed to several factors, including a growing population of immunocompromised people, climate shifts fostering better conditions for fungal proliferation, greater use of broad-spectrum antibiotics disturbing natural microbiomes, inadequate hygiene, urban expansion, and the increasing occurrence of chronic illnesses such as diabetes that make individuals more susceptible to fungal infections. Antifungals are vital in managing fungal diseases by impeding the growth and replication of fungi, either by damaging their cell wall or membrane, obstructing key enzymatic pathways, or hindering their capacity to produce essential constituents, thereby lowering the fungal burden, easing symptoms, and stopping the infection from spreading internally. As an illustration, in September 2024, data from the International Society For Infectious Diseases, a US-based non-profit organization, indicated an annual occurrence of 6.5 million invasive fungal infections, linked to roughly 3.8 million mortalities, with 2.5 million (68%; range 35-90%) of these directly caused by such infections. Consequently, the growing occurrence of fungal infections is projected to stimulate the antifungals market.

Which Key Segments Fueling The Antifungals Market?

The antifungals market covered in this report is segmented –

1) By Drug Type: Echinocandins, Azoles, Polyenes, Allylamines

2) By Route of Administration: Oral, Parenteral, Topical

3) By End users: Hospitals & Clinics, Dermatology clinics, Other Users

Subsegments:

1) By Echinocandins: Caspofungin, Micafungin, Anidulafungin

2) By Azoles: Fluconazole, Itraconazole, Voriconazole, Posaconazole, Ketoconazole

3) By Polyenes: Amphotericin B, Nystatin

4) By Allylamines: Terbinafine, Naftifine

What Are The Latest Industry Trends Transforming The Antifungals Market?

Pharmaceutical developers and manufacturers are expanding their various departments, including research and development, marketing, and manufacturing. This growth is facilitated by forming collaborations and strategic partnerships with other companies and research institutes, with the objective of broadening their product portfolios. Consequently, organizations within the anti-infective drugs market ought to explore strategic collaborations to enhance their operational scope and product offerings, which can lead to increased revenues and sustained competitiveness.

Which Leading Companies Dominate The Antifungals Market Share?

Major companies operating in the antifungals market include Pfizer Inc., Novartis International AG, Merck & Co. Inc., Bayer AG, Abbott Laboratories, Sanofi S.A., Kramer Laboratories Inc., GlaxoSmithKline plc, Gilead Sciences Inc., Basilea Pharmaceutica AG, Sigma-Aldrich, Astellas Pharma Inc., Janssen Pharmaceutica NV, Zydus Cadila Healthcare Ltd., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma Co. Ltd., Scynexis Inc., Mayne Pharma Inc., Cosmo Pharmaceuticals NV, Leadiant Biosciences Inc, Glenmark Pharmaceuticals Limited, Cidara Therapeutics, MATINAS BIOPHARMA, Mylan N.V., Perrigo Company plc, Wockhardt Ltd., Lupin Limited, Dr. Reddy’s Laboratories Ltd, Torrent Pharmaceuticals Ltd., Hikma Pharmaceuticals PLC, Mayne Pharma Group Limited, Fresenius Kabi AG, Baxter International Inc., Akorn Operating Company LLC, Amphastar Pharmaceuticals Inc., Mylan Institutional LLC, West-Ward Pharmaceuticals Corp., Gland Pharma Limited, Aurobindo Pharma Limited

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/antifungals-global-market-report

Which Region Currently Holds The Largest Share Of The Antifungals Market?

North America was the largest region in the drugs for antifungals market in 2024. The Middle East is expected to be the fastest-growing region in the antifungals market. The regions covered in the antifungals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Antifungals Market Report:

https://www.thebusinessresearchcompany.com/customise?id=2442&type=smp

Browse Through More Reports Similar to the Global Antifungals Market 2025, By The Business Research Company

Gastrointestinal Drug Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastrointestinal-drug-global-market-report

Smart Pills Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/smart-pills-global-market-report

Organ On Chip Market 2025

https://www.thebusinessresearchcompany.com/report/organ-on-chip-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Is The Predicted Market Size Of The Antifungals Industry By 2029?

The market size of antifungals has shown robust growth in the past few years. Expectations are that it will expand from $27.16 billion in 2024 to $29.6 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 9.0%. The substantial growth witnessed during the historical period can be credited to the prevalence of fungal diseases, the rise in the elderly population, the development of healthcare infrastructure, and increased awareness and education.

The market size of antifungals is projected to experience significant growth in the coming years. It is expected to reach ” $41.2 billion by 2029, with a compound annual growth rate (CAGR) of 8.6%. This growth in the forecast period can be ascribed to factors such as the emergence of new fungal strains, regulatory approval processes, global health worries, augmented spending on healthcare, as well as the education and awareness of patients. Notable trends shaping the forecast period include the advancement of antifungal drug research and improvements, a focus on e-health and telemedicine, along with collaborations and strategic partnerships.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2442&type=smp

What Growth-Enabling Forces Are Impacting The Antifungals Market?

The antifungals market is predicted to grow as a result of the rising prevalence of fungal infections. These infections are created by the infiltration and proliferation of fungi either inside or on the surface of the body, affecting organs such as the skin, nails, lungs, and mucous membranes. The increased occurrence of these infections can be attributed to various factors, including a rise in immunocompromised individuals, conditions conducive to fungal growth due to climate change, disruption of natural microbiomes through the overuse of broad-spectrum antibiotics, insufficient hygiene, urbanization, and a surge in chronic diseases like diabetes which make people more susceptible to such infections. Antifungals have a crucial part in treating fungal diseases by curbing the fungi’s growth and reproduction. This is generally done by either disrupting the fungi’s cell wall or membrane, blocking vital enzymatic processes, or hindering their ability to concoct essential components thereby lowering fungal load, calming symptoms, and preventing the infection from spreading inside the body. For example, the US-based not-for-profit organization International Society For Infectious Diseases recorded an annual incident rate of 6.5 million invasive fungal infections in September 2024. These were associated with roughly 3.8 million fatalities, of which 2.5 million (68%, with a range of 35-90%) were linked directly to the infections. Consequently, the increasing incidence of these infections is likely to stimulate the antifungals market.

Which Segment Accounts For The Largest Share In The Antifungals Market?

The antifungals market covered in this report is segmented –

1) By Drug Type: Echinocandins, Azoles, Polyenes, Allylamines

2) By Route of Administration: Oral, Parenteral, Topical

3) By End users: Hospitals & Clinics, Dermatology clinics, Other Users

Subsegments:

1) By Echinocandins: Caspofungin, Micafungin, Anidulafungin

2) By Azoles: Fluconazole, Itraconazole, Voriconazole, Posaconazole, Ketoconazole

3) By Polyenes: Amphotericin B, Nystatin

4) By Allylamines: Terbinafine, Naftifine

Which Long-Term Trends Will Play A Crucial Role In The Antifungals Market?

Pharmaceutical companies involved in the creation and production of drugs are enhancing numerous areas of their operation, including research and development, marketing, and production, by joining forces with other businesses and research institutions in order to diversify their range of products. Hence, firms operating in the anti-infective drugs sector should contemplate strategic partnerships as a means to widen their reach, diversify their product range, increase earnings and remain competitive in the market.

Which Companies Hold A Competitive Edge In The 503 Market?

Major companies operating in the antifungals market include Pfizer Inc., Novartis International AG, Merck & Co. Inc., Bayer AG, Abbott Laboratories, Sanofi S.A., Kramer Laboratories Inc., GlaxoSmithKline plc, Gilead Sciences Inc., Basilea Pharmaceutica AG, Sigma-Aldrich, Astellas Pharma Inc., Janssen Pharmaceutica NV, Zydus Cadila Healthcare Ltd., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma Co. Ltd., Scynexis Inc., Mayne Pharma Inc., Cosmo Pharmaceuticals NV, Leadiant Biosciences Inc, Glenmark Pharmaceuticals Limited, Cidara Therapeutics, MATINAS BIOPHARMA, Mylan N.V., Perrigo Company plc, Wockhardt Ltd., Lupin Limited, Dr. Reddy’s Laboratories Ltd, Torrent Pharmaceuticals Ltd., Hikma Pharmaceuticals PLC, Mayne Pharma Group Limited, Fresenius Kabi AG, Baxter International Inc., Akorn Operating Company LLC, Amphastar Pharmaceuticals Inc., Mylan Institutional LLC, West-Ward Pharmaceuticals Corp., Gland Pharma Limited, Aurobindo Pharma Limited

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/antifungals-global-market-report

Which Region Is Forecasted To Lead The Antifungals Market In The Coming Years?

North America was the largest region in the drugs for antifungals market in 2024. The Middle East is expected to be the fastest-growing region in the antifungals market. The regions covered in the antifungals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=2442&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only._x000D_

_x000D_

#What Does the Forecast Indicate for the Photodynamic Therapy Market From 2025 to 2029?#_x000D_

In recent years, the antifungals market has seen significant growth. The market value is projected to increase from $27.16 billion in 2024 to $29.6 billion in 2025 with a compound annual growth rate (CAGR) of 9.0%. Factors contributing to the growth in the historic period include the prevalence of fungal diseases, the aging population, developments in healthcare infrastructure, and an increase in awareness and education._x000D_

_x000D_

The size of the antifungals market is predicted to experience significant expansion in the upcoming years. It is projected to increase to “$41.2 billion in 2029 with a compound annual growth rate (CAGR) of 8.6%. The growth expected in this period is due to factors such as the emergence of new fungal strains, approval from regulatory bodies, global health issues, improved healthcare expenditure, patient enlightenment, and awareness. Key trends for the forecast period involve research and development, telemedicine and e-health, progress in the development of antifungal drugs, and collaborative efforts and partnerships._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=2442&type=smp_x000D_

_x000D_

#What Elements Are Contributing To Growth In The Photodynamic Therapy Market?#_x000D_

The escalating occurrence of skin cancer is instrumental in driving the growth of the market for photodynamic therapy. Skin cancer is noted as the most prevalent amongst all forms of cancer. Melanoma, although constituting approximately just 1% of skin cancers, is associated with a significant number of skin cancer fatalities. Photodynamic therapy (PDT) leverages a light-sensitizing medication and intensive light to eradicate cancerous cells. The practitioner applies a lotion containing a light-sensitizing chemical to the skin cancer and the vicinity surrounding it. For example, in January 2024, the American Cancer Society, a professional organization based in the US, stated that skin cancer is the primary cancer in the US, with melanoma accounting for around 1% of cases, but responsible for most skin cancer deaths. Additionally, around 100,640 novel melanoma cases are anticipated to be diagnosed in 2024 in the US, of which roughly 59,170 are expected in men and 41,470 in women. Approximately 8,290 melanoma-associated deaths are also projected, which include around 5,430 men and 2,860 women. Consequently, the rising rates of skin cancer are foreseen to stimulate the growth of the photodynamic therapy market in the future years._x000D_

_x000D_

_x000D_

The antifungals market covered in this report is segmented – _x000D_

_x000D_

1) By Drug Type: Echinocandins, Azoles, Polyenes, Allylamines _x000D_

2) By Route of Administration: Oral, Parenteral, Topical _x000D_

3) By End users: Hospitals & Clinics, Dermatology clinics, Other Users _x000D_

_x000D_

Subsegments:_x000D_

1) By Echinocandins: Caspofungin, Micafungin, Anidulafungin _x000D_

2) By Azoles: Fluconazole, Itraconazole, Voriconazole, Posaconazole, Ketoconazole _x000D_

3) By Polyenes: Amphotericin B, Nystatin _x000D_

4) By Allylamines: Terbinafine, Naftifine_x000D_

_x000D_

#What Future Market Trends Are Projected For The Photodynamic Therapy Industry?#_x000D_

Pharmaceutical developers and producers are expanding different divisions, including research and development, marketing, and manufacturing, through cooperative efforts and strategic alliances with other businesses and research facilities to enhance their product range. Thus, organizations in the anti-infective drugs market should contemplate about strategic partnerships to expand their reach and product offerings, thereby boosting income and maintaining market competitiveness._x000D_

_x000D_

#Who Are The Key Contributors To Growth In The Photodynamic Therapy Market?#_x000D_

Major companies operating in the antifungals market include Pfizer Inc., Novartis International AG, Merck & Co. Inc., Bayer AG, Abbott Laboratories, Sanofi S.A., Kramer Laboratories Inc., GlaxoSmithKline plc, Gilead Sciences Inc., Basilea Pharmaceutica AG, Sigma-Aldrich, Astellas Pharma Inc., Janssen Pharmaceutica NV, Zydus Cadila Healthcare Ltd., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma Co. Ltd., Scynexis Inc., Mayne Pharma Inc., Cosmo Pharmaceuticals NV, Leadiant Biosciences Inc, Glenmark Pharmaceuticals Limited, Cidara Therapeutics, MATINAS BIOPHARMA, Mylan N.V., Perrigo Company plc, Wockhardt Ltd., Lupin Limited, Dr. Reddy’s Laboratories Ltd, Torrent Pharmaceuticals Ltd., Hikma Pharmaceuticals PLC, Mayne Pharma Group Limited, Fresenius Kabi AG, Baxter International Inc., Akorn Operating Company LLC, Amphastar Pharmaceuticals Inc., Mylan Institutional LLC, West-Ward Pharmaceuticals Corp., Gland Pharma Limited, Aurobindo Pharma Limited_x000D_

_x000D_

_x000D_

https://www.thebusinessresearchcompany.com/report/antifungals-global-market-report_x000D_

_x000D_

#Which Region Is Projected To Lead The Photodynamic Therapy Market By 2025?#_x000D_

North America was the largest region in the drugs for antifungals market in 2024. The Middle East is expected to be the fastest-growing region in the antifungals market. The regions covered in the antifungals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa_x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=2442&type=smp_x000D_

_x000D_

#About The Business Research Company:#_x000D_

_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 7882 955267 & +91 8897263534_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model